Table of Contents
Overview
New York, NY – July 15, 2025: The Cancer Biomarkers Market is witnessing substantial growth. It is expected to reach USD 98.1 billion by 2033, rising from USD 30.2 billion in 2023, at a CAGR of 12.5% during 2024–2033. Key growth drivers include the increasing global cancer burden and the shift toward precision medicine. Biomarkers help in early diagnosis, disease prognosis, and predicting treatment outcomes. The rising adoption of targeted therapies is further accelerating market expansion. Government initiatives to enhance cancer diagnostics and screening are also fueling demand for advanced biomarker technologies.
Cancer biomarkers are measurable biological molecules found in blood, tissues, or fluids. They can be genetic, epigenetic, proteomic, or metabolic indicators. These markers are used in diagnosing cancers like lung, breast, colorectal, and prostate. They help in determining disease stages, guiding therapeutic decisions, and tracking treatment response. With a surge in personalized medicine, biomarkers enable oncologists to customize treatment plans for individual patients. Their use reduces trial-and-error in therapy selection and improves clinical outcomes, making them indispensable in oncology care.
According to global estimates, around 20 million people were diagnosed with cancer in 2022. Despite improved survival, nearly 10 million people died from the disease. Moreover, 53.5 million individuals were living within five years of a cancer diagnosis. The World Health Organization (WHO) reports that less than 40% of countries provide comprehensive cancer treatment and palliative care. This reveals a critical care gap, especially in low- and middle-income nations. Strengthening cancer biomarker access could bridge diagnostic disparities and improve early intervention.
The market is rapidly evolving with innovations in liquid biopsies and real-time diagnostics. Liquid biopsies allow non-invasive detection of cancer biomarkers through blood samples. These technologies support earlier cancer detection and enable disease monitoring without surgical intervention. Additionally, AI and machine learning are revolutionizing biomarker discovery by identifying complex patterns in genomic data. Emerging players are also developing multi-omics platforms combining genomics, proteomics, and metabolomics. These advancements are set to transform cancer care, offering accurate, efficient, and patient-specific diagnostic solutions globally.
Key Takeaways
- In 2023, the cancer biomarkers market earned USD 30.2 billion, growing at a 12.5% CAGR, and is forecasted to reach USD 98.1 billion by 2033.
- Breast cancer biomarkers led the type segment in 2023, capturing the largest market share of 28.7% among all cancer types.
- Based on biomolecule types, genetic biomarkers dominated with a 32.6% share, highlighting their growing importance in cancer identification and treatment.
- The diagnostics application segment emerged as the market leader, holding 41.9% of total revenue, driven by rising early detection efforts.
- Within technology categories, imaging technology led the segment with a commanding 63.5% market share, showing strong adoption in cancer diagnostics.
- North America took the lead regionally, accounting for 41.1% of the global market share in 2023, supported by advanced healthcare infrastructure.
Regional Analysis
North America led the global cancer biomarkers market in 2023, accounting for a 41.1% revenue share. The region’s dominance is driven by strong demand for early cancer detection and rapid advancements in precision medicine. Recent regulatory approvals have supported growth, such as the USFDA’s approval of Illumina’s cancer biomarker test in August 2024. In addition, Cizzle Biotechnology Holdings plc announced a U.S.-based partnership in June 2024 to include its CIZ1B biomarker in a major cancer study. Increasing research activity, strong clinical infrastructure, and government funding are all fueling biomarker adoption across North America.
The Asia Pacific region is projected to register the highest CAGR over the forecast period. Rising cancer prevalence and investment in diagnostic technologies are driving this growth. In August 2023, Quest Diagnostics collaborated with Envision Sciences to launch a new prostate cancer biomarker test, developed from research by the University of South Australia. Countries like China, Japan, and India are rapidly expanding healthcare infrastructure and promoting personalized medicine. Government initiatives focused on early diagnosis and cancer research are expected to boost the adoption of biomarker-based testing throughout the region.
Segmentation Analysis
The breast cancer segment dominated the cancer biomarkers market in 2023, capturing a 28.7% share. This growth is attributed to the global rise in breast cancer cases and the increasing demand for early detection methods. Biomarkers like BRCA1 and BRCA2, combined with advancements in liquid biopsy technologies, are significantly improving early diagnosis and monitoring. Greater awareness through breast cancer screening campaigns and personalized treatment strategies is also boosting demand. Continued investments in research to discover novel breast cancer-specific biomarkers are expected to drive further segment growth.
In the biomolecule segment, genetic biomarkers held the largest market share at 32.6% in 2023. Their dominance is fueled by the growing emphasis on precision medicine and the identification of gene mutations that contribute to cancer progression. Next-generation sequencing (NGS) is accelerating the discovery and validation of these genetic markers. The widespread use of genetic testing, especially among high-risk groups, is further supporting market expansion. Additionally, research focused on actionable genetic mutations is expected to advance biomarker-driven treatment in cancers like breast and colorectal cancer.
The diagnostics application segment led with a 41.9% revenue share in 2023, owing to increased demand for accurate and early cancer detection. Biomarker-based diagnostic tools enhance the efficiency of screening and diagnosis, enabling timely interventions. The shift toward non-invasive methods, including liquid biopsy and imaging-supported biomarker detection, is a major trend. Growing government-led screening programs and the integration of biomarkers into standard diagnostic assays are projected to accelerate growth, particularly in prevalent cancers like lung and breast cancer.
In terms of technology, imaging techniques dominated the market with a 63.5% share in 2023. This growth reflects the expanding use of PET, CT, and MRI scans, especially those enhanced by biomarker-based contrast agents. These technologies play a crucial role in detecting, diagnosing, and tracking the progression of various cancers. The demand for real-time, non-invasive imaging is rising as clinicians seek more accurate tools to monitor treatment response. Moreover, the adoption of advanced imaging solutions in oncology clinical trials is anticipated to further strengthen the imaging technology segment.
By Type
- Breast cancer
- Liver cancer
- Colorectal cancer
- Prostate cancer
- Cervical cancer
- Lung cancer
- Others
By Biomolecule
- Genetic Biomarkers
- Metabolic Biomarkers
- Proteomic Biomarkers
- Epigenetic Biomarkers
- Others
By Application
- Drug discovery & Development
- Diagnostics
- Personalized medicine
- Others
By Technology
- Imaging Technology
- OMICS
Key Players Analysis
Key players in the cancer biomarkers market are actively developing innovative diagnostic products to improve early cancer detection and support personalized treatment approaches. These companies are heavily focused on advanced diagnostic technologies that enhance the precision and speed of cancer diagnosis. Strategic initiatives, such as product launches, mergers, and partnerships, are commonly adopted to strengthen their market presence and stay ahead of the competition.
Most leading companies invest significantly in research and development to discover novel biomarkers and improve existing test accuracy. Collaborations with pharmaceutical firms and research institutions are helping to accelerate the creation of targeted therapies. Expanding into emerging markets allows them to access a larger patient base and boost revenues. Moreover, obtaining regulatory approvals and raising awareness among healthcare professionals remain key priorities to drive product adoption and maximize market reach.
- Siemens Healthineers
- Seegene Technologies Inc.
- Roche
- Meso Scale Diagnostics LLC
- LES LABORATOIRES SERVIER
- Koninklijke Philips N.V.
- Exact Sciences
- Bio-Rad Laboratories Inc.
- Abbott Laboratories
Emerging Trends
1. Shift Toward Non-Invasive Testing
Cancer testing is becoming less invasive with the growing use of liquid biopsies. These tests use blood or other body fluids instead of tissue samples. They make cancer detection faster, easier, and less painful for patients. Unlike traditional biopsies, liquid biopsies are safer and can be done more frequently. This allows doctors to detect cancer earlier and track it more often during treatment. As technology improves, more healthcare providers are adopting this method. The trend is expected to grow, especially in screening and monitoring aggressive or recurring cancers.
2. AI in Biomarker Discovery
Artificial intelligence (AI) is playing a bigger role in cancer research. It helps doctors and scientists process large volumes of genetic and clinical data. AI can find patterns that are too complex for humans to detect easily. These patterns help in discovering new biomarkers that can improve diagnosis and treatment. AI also shortens the time it takes to move from research to real-world application. This means patients can get more accurate tests and personalized therapies faster. The use of AI in cancer biomarker research is expected to grow rapidly in the coming years.
3. Multi-Omics Integration
Researchers are now combining different fields like genomics, proteomics, and metabolomics—a method called multi-omics. This gives a full, detailed view of how cancer develops and behaves in the body. Each “omic” layer provides unique information. Together, they help in identifying better biomarkers and understanding treatment responses. Multi-omics can also predict how a patient might react to a drug. This helps in choosing the most effective therapy. As multi-omics technology becomes more accessible, it will likely transform cancer diagnosis and personalized treatment planning.
4. Personalized Medicine on the Rise
Cancer treatment is shifting toward personalized medicine, and biomarkers are at the core of this change. Doctors now use specific biomarkers to design treatment plans tailored to each patient’s biology. This approach helps avoid the “one-size-fits-all” method and reduces side effects. Personalized medicine improves outcomes by using therapies that are more likely to work for a particular person. As more biomarkers are discovered, treatment decisions will become even more targeted. This trend is changing how we treat cancer and offers hope for more successful long-term outcomes.
5. Biomarkers for Monitoring Treatment
Biomarkers are not just for detecting cancer anymore. They are now widely used to monitor how well a treatment is working. Doctors can test biomarkers at regular intervals during therapy. If levels drop or change, it may signal that the treatment is working—or not. This helps in adjusting treatment early and avoiding ineffective drugs. Real-time monitoring with biomarkers also reduces unnecessary treatments. It supports better decision-making and can lead to improved survival rates. As this practice becomes common, it will play a key role in cancer management and follow-up care.
Use Cases
1. Early Detection of Cancer
Cancer biomarkers are crucial for early diagnosis. For example, BRCA1 and BRCA2 are used to detect breast cancer risk before symptoms appear. Women who carry these mutations have a 60% to 80% lifetime risk of developing breast cancer. By identifying this risk early, doctors can suggest preventive measures like regular screenings, lifestyle changes, or preventive surgery. Early detection leads to faster treatment and better outcomes. This use of biomarkers helps reduce cancer-related deaths. As awareness grows, more high-risk individuals are opting for genetic testing to stay ahead of potential cancer development.
2. Selecting the Right Treatment
Biomarkers help doctors choose the most effective treatment for each patient. In lung cancer, the EGFR mutation acts as a guide. If a patient has this mutation, they can receive targeted therapies instead of general chemotherapy. These targeted drugs attack the cancer cells more precisely and cause fewer side effects. Patients respond better and often live longer. Using biomarkers to match the treatment with the patient’s unique cancer profile is a major step in personalized medicine. It improves success rates and reduces the use of unnecessary or less-effective therapies.
3. Monitoring Treatment Progress
Doctors use cancer biomarkers to see how well a treatment is working. In prostate cancer, the PSA (Prostate-Specific Antigen) level is commonly tracked. If PSA levels drop during treatment, it usually means the cancer is shrinking or responding. If the levels stay high or increase, the treatment may need to change. This regular monitoring helps doctors make faster decisions. Patients benefit because they avoid ineffective treatments and get better results. Biomarker testing during treatment gives a clear picture of progress and allows for real-time adjustments, improving overall care.
4. Predicting Cancer Recurrence
Some cancer biomarkers can signal the return of cancer after treatment. For example, CEA (Carcinoembryonic Antigen) is often used in colorectal cancer follow-ups. If CEA levels rise after surgery or chemotherapy, it may suggest that the cancer is coming back. This alerts doctors to take quick action, such as starting new treatment or doing more tests. Predicting recurrence helps patients stay ahead of the disease and improves survival chances. Biomarkers play a key role in post-treatment surveillance, helping both doctors and patients stay proactive in long-term care.
5. Screening High-Risk Populations
People with a family history of cancer often undergo genetic testing to check for inherited biomarkers. Individuals with this condition are advised to start regular screening at a younger age. Biomarker testing in these cases helps identify risk early and supports better prevention strategies. It also helps families understand their genetic risks. This proactive use of biomarkers leads to earlier diagnosis, better monitoring, and potentially life-saving interventions for high-risk individuals.
Conclusion
The cancer biomarkers market is undergoing rapid transformation, driven by rising global cancer cases, growing demand for early detection, and the shift toward personalized medicine. Biomarkers are playing a pivotal role in improving diagnosis, guiding treatment decisions, and monitoring therapy effectiveness. Technological advancements like liquid biopsies, AI-driven discovery, and multi-omics platforms are expanding clinical possibilities and patient outcomes. With strong regional leadership in North America and high growth potential in Asia Pacific, the market is well-positioned for continued expansion. As awareness and access improve, cancer biomarkers are set to become central to global oncology care strategies.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
